Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Vor Bio reported financial results for Q1 2026 with $491.5 million in cash to fund operations into early 2029, ongoing global Phase 3 trials for telitacicept in generalized myasthenia gravis and primary Sjögren's disease, and anticipates topline data in H1 2027. The company highlights the potential of telitacicept to become a foundational therapy i…